AV Medical Technologies has received approval from the US Food and Drug Administration (FDA) for its Chameleon angioplasty balloon catheter.
Featuring Proximal Injection Port (PIP) technology, Chameleon is claimed to be the only angioplasty balloon catheter that enables for simultaneous balloon inflation and intravascular injection of fluids while maintaining guidewire access.
PIP technology integrates proprietary catheter construction, which allows for targeted fluid delivery with an easy to use design.
AV Medical Technologies CEO Limor Sandach said: "Our entire team is thrilled with this news. Chameleon represents the first product to include our proprietary Proximal Injection Port design.
"Over two million angioplasty balloon catheters are used annually to maintain dialysis access worldwide. This is an exciting advancement to catheter-based interventions and offers potential for development into additional products."
Established in 2012, AV Medical is involved in developing solutions to improve visualization during catheter-based interventions, while reducing procedural steps.